Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Rx Will Allow Exceptions To Two-Drug-Per-Class Rule

This article was originally published in The Pink Sheet Daily

Executive Summary

Medicare prescription drug plans may petition the Centers for Medicare & Medicaid Services to allow coverage of a single drug in classes where only two drugs exist, CMS' final Medicare Rx regulations state

You may also be interested in...



USP's Finalized Model For Medicare Rx Formularies Retains 146 Drug Groups

Overall, the model guidelines resemble the version proposed by USP in August but include revisions to specific therapeutic categories and pharmacologic classes. Proton pump inhibitors are placed in a separate drug class; SSRIs/SNRIs remain off the formal chart.

GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds

New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS060926

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel